Mechanisms of Anti-Myocardial Ischemia Reperfusion Injury of Qishen Yiqi Dropping Pills Based on UHPLC-MS/MS and Network Pharmacology

doi:10.19803/j.1672-8629.20250620

Abstract

Abstract: Objective To identify the chemical constituents and blood-entering components of Qishen Yiqi dropping pills (QSYQ) using UHPLC-MS/MS, and to investigate its mechanism of action against myocardial ischemia-reperfusion injury (MIRI). Methods Chromatographic separation was performed on an ACQUITY UPLC HSS T3 column under gradient elution with a mobile phase consisting of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). Data acquisition was conducted in both positive and negative ionization modes using a UPLC I-Class system coupled with a Synapt G2-Si Q-TOF mass spectrometer. Data processing was performed using the Unifi software's natural product workflow. A theoretical mass spectrometry database of 6400 natural products was used for identification of chemical constituents and blood-entering components. Potential targets of the identified blood-entering components and MIRI-related targets were retrieved from databases. Protein-protein interaction (PPI) networks were constructed to identify core targets of QSYQ against MIRI, followed by Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Results A total of 194 compounds were identified in QSYQ, while another 24 compounds were identified in the plasma of rats administered with QSYQ. The prototype components absorbed into the bloodstream included saponins and diterpenoid quinones. Network pharmacology analysis suggested that QSYQ exerted anti-MIRI effects by acting on key pathways such as the PI3K-AKT and HIF-1 signaling pathways. Conclusion The results of this study indicate that the prototype components absorbed into the bloodstream are likely the effective constituents of QSYQ. This research provides a reference for investigation into the pharmacodynamic material basis and pharmacological mechanisms of QSYQ.

Key words: Qishen Yiqi Dropping Pills, Blood-Entering Components, Saponins, Diterpenoid Quinones, Myocardial Ischemia-Reperfusion Injury, UHPLC-MS/MS, Rat, Network Pharmacology

CLC Number:

LIU Shuling, JIANG Huiru, CUI Herong, ZHANG Zehan, SHANG Hongcai. Mechanisms of Anti-Myocardial Ischemia Reperfusion Injury of Qishen Yiqi Dropping Pills Based on UHPLC-MS/MS and Network Pharmacology[J]. Chinese Journal of Pharmacovigilance, 2025, 22(11): 1246-1252.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250620

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I11/1246

References

[1] SHANG H, ZHANG J, YAO C, et al.Qi-Shen-Yi-Qi Dripping Pills for the Secondary Prevention of MyocardialInfarction: a Randomised Clinical Trial[J]. Evid Based Complement Alternat Med, 2013, 2013: 738391.
[2] MAO J, ZHANG J, LAM C, et al.Qishen Yiqi Dripping Pills for Chronic Ischaemic Heart Failure: Results of the CACT-IHF Randomized Clinical Trial[J]. ESC Heart Fail, 2020, 7(6): 3881-3890.
[3] HE GX, XIE J, JIANG H, et al.Effects of Qishen Yiqi Dripping Pills in ReducingMyocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: a Pilot Randomized Study[J]. Chin J Integr Med, 2018, 24(3): 193-199.
[4] LIN SQ, WEI XH, HUANG P, et al.QiShenYiQi Pills^® Prevent Cardiac Ischemia-Reperfusion Injury via Energy Modulation[J]. Int J Cardiol, 2013, 168(2):967-974.
[5] HAN JY, LI Q, PAN CS, et al.Effects and Mechanisms of QiShenYiQi Pills and Major Ingredients on Myocardial Microcirculatory Disturbance, Cardiac Injury and Fibrosis Induced by Schemia-Reperfusion[J]. Pharmacol Res, 2019, 147:104386.
[6] ZHENG QN, WEI XH, PAN CS, et al.QiShenYiQi Pills^® Ameliorates Ischemia/Reperfusion-Induced Myocardial Fibrosis Involving RP S19-Mediated TGFβ1/Smads Signaling Pathway[J]. Pharmacol Res, 2019, 146: 104272.
[7] YANG HJ, LI XY, CHEN P, et al.The Review of Modern Advances in Basic Research on Compound Formulas of Traditional Chinese Medicine[J]. Bulletin of National Natural Science Foundation of China(中国科学基金), 2024, 38(3): 387-395.
[8] XU SY, BIAN RL, CHEN X, et al.Experimental Methodology of Pharmacology(药理实验方法学)[M]. Beijing: The People's Health Press Co., Ltd , 2002: 1937.
[9] WANG X, ZHANG R, ZENG N, et al.Panax Notoginseng Saponins Dually Modulates Autophagy in Gastric Precancerous Lesions Complicated with Myocardial Ischemia-Reperfusion Injury Model through the PI3K/AKT/mTOR Pathway[J]. Biomed Pharmacother, 2024, 178: 117268.
[10] XIA J, CHEN C, SUN Y, et al.Panax Quinquefolius Saponins and Panax Notoginseng Saponins Attenuate Myocardial Hypoxia-Reoxygenation Injury by Reducing Excessive Mitophagy[J]. Cell Biochem Biophys, 2024, 82(2): 1179-1191.
[11] TU L, PAN CS, WEI XH, et al.Astragaloside IV Protects Heart from Ischemia and Reperfusion Injury via Energy Regulation Mechan-isms[J]. Microcirculation, 2013, 20(8): 736-747.
[12] YANG L, LIU N, YANG Y.Astragaloside IV-Induced BMSC Exosomes Promote Neovascularization and Protect Cardiac Function in Myocardial Infarction Mice via the miR-411/HIF-1αAxis[J].J Liposome Res, 2024, 34(3): 452-463.
[13] KE L, ZHENG Z, YE S, et al.Tanshinone I Alleviates Post-Ischemic Myocardial Injury by Targeting TGFBR1 and Modulating the TGF-β Signaling Pathway[J]. Phytomedicine, 2025, 145: 156994.
[14] WANG S, SUN L, ZHU Z, et al.Cryptotanshinone Alleviates Myocardial Ischemia and Reperfusion Injury in Rats to Mitigate ER Stress-Dependent Apoptosis by Modulating the JAK1/STAT3 Axis[J]. Am J Transl Res, 2022, 14(7): 5024-5039.
[15] YUAN X, XIANG Y, ZHU N, et al.Salvianolic Acid A Protects against Myocardial Ischemia/Reperfusion Injury by Reducing Platelet Activation and Inflammation[J]. Exp Ther Med, 2017, 14(2): 961-966.
[16] YANG Y, SUN Z, SUN X, et al.Protective Effect of Salvianolic Acid B against Myocardial Ischemia/Reperfusion Injury: Preclinical Systematic Evaluation and Meta-Analysis[J]. Front Pharmacol, 2024, 15: 1452545.
[17] WANG P, ZHANG S, LI X, et al.Salvianolic Acid a Inhibits the Activation and Aggregation of Platelets in Patients with Acute Coronary Syndrome[J]. Medicine (Baltimore), 2025, 104(29): e43305.
[18] SHARMA J, BHARGAVA P, MISHRA P, et al.Molecular Mechanisms of Flavonoids in Myocardial Ischemia Reperfusion Injury: Evidence from in-vitro and in-vivo Studies[J]. Vascul Pharmacol, 2024, 155: 107378.
[19] BIRNBAUM Y, VILAHUR G.Flavonoids for Myocardial Ischemia-Reperfusion Injury[J]. Cardiovasc Drugs Ther, 2025, 39(4): 705-706.
[20] YAMADA M, OMIYA K, NAKADATE Y, et al.Roles of Equol and the PI3K/AktSignaling Pathway in the Cardioprotective Effects of Enteral Daidzein against Ischemia-Reperfusion Injury in Isolated Rat Hearts[J]. Steroids, 2025, 220: 109637.
[21] GUO L, CAO JD, LEI MX, et al.Clinical Efficacy and Safety of Qishen Yiqi Dripping Pills Combined with Western Medicine in the Treatment of Heart Failure with Preserved Ejection Fraction[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药), 2024, 17(28): 41-43.
[22] ZHAO YD, SHI CC, SU QX, et al.Research Progress on Extraction and Isolation, Biosynthesis, Biological Activities of Astragalosides and Its Application Prospects[J]. Chinese Traditional and Herbal Drugs(中草药), 2025, 56(10): 3759-3770.
[23] WEI BQ, CHEN L, ZHANG XY, et al.Research Progress on Extraction, Structure, Biological Activity and Application of Panax Notoginseng Saponin Science and Technology of Food Industry[J]. Science and Technology of Food Industry(食品工业科技), 2025, 46(7): 415-424.